UCB to File Two More Cimzia Arthritis Indications This Year, Tables RA Drug

UCB plans to submit marketing applications for Cimzia in psoriatic arthritis and axial spondyloarthritis, including ankylosing spondylitis, to the FDA and EU by the end of the year.  The filings follow positive Phase III results for the drug in both indications reported earlier this year.
Washington Drug Letter